1082041-34-6 Usage
General Description
5-Bromo-4-methyl-1H-indazole is a chemical compound with the molecular formula C8H7BrN2. It is a heterocyclic compound with a five-membered ring containing two nitrogen atoms. This chemical is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals, as well as in research and development for various applications. 5-Bromo-4-methyl-1H-indazole may also have potential applications in the field of organic synthesis and medicinal chemistry. As a highly reactive compound, it requires careful handling and storage, and should only be used by trained professionals in appropriate laboratory settings. Its precise properties and applications may vary based on its specific use and formulation.
Check Digit Verification of cas no
The CAS Registry Mumber 1082041-34-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,8,2,0,4 and 1 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1082041-34:
(9*1)+(8*0)+(7*8)+(6*2)+(5*0)+(4*4)+(3*1)+(2*3)+(1*4)=106
106 % 10 = 6
So 1082041-34-6 is a valid CAS Registry Number.
1082041-34-6Relevant articles and documents
Diastereoselective Copper-Mediated Conjugate Addition of Functionalized Magnesiates for the Preparation of Bisaryl Nrf2 Activators
Glogowski, Michal P.,Matthews, Jay M.,Lawhorn, Brian G.,Minbiole, Kevin P. C.
, p. 3120 - 3137 (2021/03/01)
A two-step metal-halogen exchange and diastereoselective copper-mediated Michael addition onto a complex α,β-unsaturated system has been developed and applied toward the synthesis of bisaryl Nrf2 activators. Optimization of metal-halogen exchange using (n
OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS
-
Page/Page column 25, (2012/11/13)
Oxadiazole substituted indazole derivatives of formula (I) or pharmaceutical salts thereof having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptors are disclosed.